Literature DB >> 26905520

The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.

M Fragni1, S A Bonini2, P Bettinsoli2, S Bodei2, D Generali3, A Bottini4, P F Spano2, M Memo2, S Sigala2.   

Abstract

Preclinical data indicate a direct anti-tumor effect of zoledronic acid (ZA) outside the skeleton, but its molecular mechanism is still not completely clarified. The aim of this study was to investigate the anti-cancer effects of ZA in human breast cancer cell lines, suggesting that they may in part be mediated via the miR-21/PTEN/Akt signaling pathway. The effect of ZA on cell viability was measured by MTT assay, and cell death induction was analyzed using either a double AO/EtBr staining and M30 ELISA assay. A Proteome Profiler Human Apoptosis Array was executed to evaluate the molecular basis of ZA-induced apoptosis. Cell cycle analysis was executed by flow cytometry. The effect of ZA on miR-21 expression was quantified by qRT-PCR, and the amount of PTEN protein and its targets were analyzed by Western blot. ZA inhibited cell growth in a concentration- and time-dependent manner, through the activation of cell death pathways and arrest of cell cycle progression. ZA downregulated the expression of miR-21, resulting in dephosphorilation of Akt and Bad and in a significant increase of p21 and p27 proteins expression. These results were observed also in MDA-MB-231 cells, commonly used as an experimental model of bone metastasis of breast cancer. This study revealed, for the first time, an involvement of the miR-21/PTEN/Akt signaling pathway in the mechanism of ZA anti-cancer actions in breast cancer cells. We would like to underline that this pathway is present both in the hormone responsive BC cell line (MCF-7) as well as in a triple negative cell line (MDA-MB-231). Taken together these results reinforce the use of ZA in clinical practice, suggesting the role of miR-21 as a possible mediator of its therapeutic efficacy.

Entities:  

Keywords:  Akt; Breast cancer; PTEN; Zoledronic acid; miR-21

Mesh:

Substances:

Year:  2016        PMID: 26905520     DOI: 10.1007/s00210-016-1224-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  52 in total

1.  Differential effects of bisphosphonates on breast cancer cell lines.

Authors:  R Verdijk; H R Franke; F Wolbers; I Vermes
Journal:  Cancer Lett       Date:  2006-04-18       Impact factor: 8.679

2.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Authors:  Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

Review 3.  Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology.

Authors:  Ilaria Dutto; Micol Tillhon; Ornella Cazzalini; Lucia A Stivala; Ennio Prosperi
Journal:  Arch Toxicol       Date:  2014-12-17       Impact factor: 5.153

4.  A novel high-through-put assay for screening of pro-apoptotic drugs.

Authors:  Maria Hägg; Kenneth Bivén; Takayuki Ueno; Lars Rydlander; Peter Björklund; Klas G Wiman; Maria Shoshan; Stig Linder
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

Review 6.  PI3K/PTEN signaling in tumorigenesis and angiogenesis.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Biochim Biophys Acta       Date:  2007-09-29

7.  Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.

Authors:  Masayoshi Yamaguchi; Tatyana Vikulina; M Neale Weitzmann
Journal:  Oncol Rep       Date:  2015-08-10       Impact factor: 3.906

8.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

Authors:  Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

9.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Authors:  S P Jagdev; R E Coleman; C M Shipman; A Rostami-H; P I Croucher
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

Review 10.  Focus on PTEN Regulation.

Authors:  Miriam Bermúdez Brito; Evangelia Goulielmaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2015-07-27       Impact factor: 6.244

View more
  13 in total

Review 1.  Pharmacology of bisphosphonates.

Authors:  Serge Cremers; Matthew T Drake; F Hal Ebetino; John P Bilezikian; R Graham G Russell
Journal:  Br J Clin Pharmacol       Date:  2019-02-28       Impact factor: 4.335

Review 2.  Emerging Role of MicroRNAs in mTOR Signaling.

Authors:  Yanjie Zhang; Bo Huang; Hui-Yun Wang; Augustus Chang; X F Steven Zheng
Journal:  Cell Mol Life Sci       Date:  2017-02-25       Impact factor: 9.261

3.  Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism.

Authors:  Nazila Fathi Maroufi; Vahid Vahedian; Seyed Ali Miresmaeili Mazrakhondi; Wesam Kooti; Hosein Ajami Khiavy; Roya Bazzaz; Fatemeh Ramezani; Seyed Mohammadbagher Pirouzpanah; Marjan Ghorbani; Maryam Akbarzadeh; Hamed Hajipour; Saeed Ghanbarzadeh; Mehdi Sabzichi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-02       Impact factor: 3.000

4.  Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.

Authors:  Elisa Rossini; Mariangela Tamburello; Andrea Abate; Silvia Beretta; Martina Fragni; Manuela Cominelli; Deborah Cosentini; Constanze Hantel; Federica Bono; Salvatore Grisanti; Pietro Luigi Poliani; Guido A M Tiberio; Maurizio Memo; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

5.  The anti-tumorigenic activity of A2M-A lesson from the naked mole-rat.

Authors:  Susanne Kurz; René Thieme; Ronny Amberg; Marco Groth; Heinz-Georg Jahnke; Philipp Pieroh; Lars-Christian Horn; Marlen Kolb; Klaus Huse; Matthias Platzer; Daniela Volke; Faramarz Dehghani; Anton Buzdin; Kathrin Engel; Andrea Robitzki; Ralf Hoffmann; Ines Gockel; Gerd Birkenmeier
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

6.  Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway.

Authors:  Lina Zhao; Xianyu Zhang; Shusen Cui
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

7.  Downregulated miR-21 mediates matrine-induced apoptosis via the PTEN/Akt signaling pathway in FTC-133 human follicular thyroid cancer cells.

Authors:  Quanliang Li; Shuya Zhang; Mingyu Wang; Shouguang Dong; Yan Wang; Song Liu; Tiancheng Lu; Yuqin Fu; Xiuran Wang; Guihong Chen
Journal:  Oncol Lett       Date:  2019-07-31       Impact factor: 2.967

Review 8.  AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review.

Authors:  Nico Hinz; Manfred Jücker
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

9.  miR-155 Regulates the Proliferation of Glioma Cells Through PI3K/AKT Signaling.

Authors:  Dahao Wu; Changzhen Wang
Journal:  Front Neurol       Date:  2020-04-28       Impact factor: 4.003

10.  The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.

Authors:  Dominika Rittler; Marcell Baranyi; Eszter Molnár; Tamás Garay; István Jalsovszky; Imre Károly Varga; Luca Hegedűs; Clemens Aigner; József Tóvári; József Tímár; Balázs Hegedűs
Journal:  Int J Mol Sci       Date:  2019-10-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.